Company Overview
Company Type: Private Company
Website: www.fedorapharma.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 0.20
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Fedora Pharmaceuticals Inc., a biotechnology company, engages in the discovery and development of antibiotics for life-threatening microbial drug resistance needs. It develops beta-lactamase inhibitor molecules, which are enzymes produced by bacteria that destroy the ring structure common to beta-lactam antibiotics, such as penicillin derivatives, cephalosporins, monobactams, and carbapenems. The company’s products are used in combination with various beta-lactam antibiotics for the treatment of antibiotic infections currently resistant to therapy. Fedora Pharmaceuticals Inc. was founded in 2012 and is based in Edmonton, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Micetich, Christopher G.
Chairman, Chief Executive Officer and President

Key Board Members
Name
Title
Micetich, Christopher G.
Chairman, Chief Executive Officer and President
Bush, Karen 
Member of Scientific Advisory Board
Gordon, Eric M.
Member of Scientific Advisory Board
Odynski, Ronald W.
Director
Post, Leonard E.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
4290-91A Street | Edmonton, AB | T6E 5V2 | Canada
Phone: 780-989-9845   Fax: 780-461-0196


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-22-2013
-
Private Placement
Target
Fedora Pharmaceuticals Inc.


0.20
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-22-2022
Company Conference Presentations
Fedora Pharmaceuticals Inc. Presents at 22nd Annual Healthcare Summit, Sep-22-2022
Jan-07-2019
Strategic Alliances
Fedora Pharmaceuticals and Meiji Seika Pharma Sign Basic Agreement to Establish NacuGen Therapeutics Inc., Joint Venture to Develop and Commercialize Nacubactam for Bacterial Infections
Mar-16-2015
Client Announcements
Roche, Meiji Seika Pharma and Fedora Enter into a License Agreement
Jan-13-2015
Client Announcements
Roche, Meiji Seika Pharma and Fedora Enters into a License Agreement for the Development and Commercialization of OP0595
Apr-22-2013
Private Placements
Fedora Pharmaceuticals Inc. announced that it has received CAD 0.20 million in funding.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Apr 08, 2019 05:13 AM
Fedora Pharmaceuticals Inc.
Fedora Pharmaceuticals Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 11, 2019 04:47 AM
Fedora Pharmaceuticals Inc.
Fedora Pharmaceuticals Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 10, 2018 06:10 AM
Fedora Pharmaceuticals Inc.
Fedora Pharmaceuticals Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Sep 17, 2018 07:11 AM
Fedora Pharmaceuticals Inc.
Fedora Pharmaceuticals Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Jun 18, 2018 07:28 AM
Fedora Pharmaceuticals Inc.
Fedora Pharmaceuticals Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Mar 21, 2018 05:52 AM
Fedora Pharmaceuticals Inc.
Fedora Pharmaceuticals Inc. - Company Report
Reports
7


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Micetich, Christopher G.
Chairman, Chief Executive Officer and President
780-989-9845
780-461-0196

Bush, Karen 
Member of Scientific Advisory Board
780-989-9845
780-461-0196
-
Gordon, Eric M.
Member of Scientific Advisory Board
780-989-9845
780-461-0196

Odynski, Ronald W.
Director
780-989-9845
780-461-0196

Post, Leonard E.
Director
780-989-9845
780-461-0196

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Micetich, Christopher G.
Chairman, Chief Executive Officer and President
780-989-9845
780-461-0196

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
